Objective. Rituximab (RTX) is a B cell depleting agent used to induce and maintain remission in patients with granulomatosis with polyangiitis (GPA). As the development of hypogammaglobulinaemia in GPA patients on long-term RTX has not been addressed, the aim of this study was to investigate changes in immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term RTX maintenance therapy in GPA.
Introduction
Rituximab (RTX) is a chimeric humanmouse monoclonal antibody that gives rapid sustained depletion of premature and mature B cells through antibody-dependent, complement-mediated cellular cytotoxicity and apoptosis [1] . RTX reduces autoantibody-producing precursor plasma cells, inhibits B cell interaction with autoreactive T cells and decreases the level of soluble factors secreted by B cells [1] . B cells usually return to pre-treatment levels within 12 months after RTX [2] .
RTX is approved for the treatment of RA and ANCAassociated vasculitis (AAV) and is used off-label in a large number of autoimmune conditions [3] . In AAV, RTX is used for both induction [4, 5] and maintenance [610] of remission through iterative RTX infusions. Relevant side effects include late-onset neutropenia, hypogammaglobulinaemia development and an increased risk of infection [1114] .
However, the long-term safety profile of RTX in AAV is not as well documented as in RA [1315] . RTX is associated with a greater decrease in Ig levels in RA patients treated with a cumulative dose of 55 g [16] and in AAV patients previously treated with CYC [17] . In light of its multiple immune-modulating mechanisms, the long-term effects of RTX on natural autoantibody production and T and NK cell levels are of special interest.
To analyse the impact on Ig levels and lymphocyte subpopulations and to determine risk factors for hypogammaglobulinaemia during long-term RTX maintenance, we investigated the course of these variables in 29 patients with granulomatosis with polyangiitis (GPA) who received RTX 55 g at our centre.
Patients and methods
Since 2001 the vasculitis disease registry (Nordnorsk Vaskulittregister) has collected information on disease presentation and course from patients with an established diagnosis of primary vasculitis followed at the University Hospital of North Norway. All patients gave informed written consent at registry inclusion according to the Declaration of Helsinki. In accordance with the standards applied in Norway, the study did not require formal ethical approval.
This analysis concerns 29 GPA patients from that registry who were treated with RTX between April 2004 and September 2011. All patients satisfied the 1990 ACR classification and/or Chapel Hill Consensus Conference criteria.
The patients-15 men (52%) and 14 women (48%) with a median age of 50 years (range 975) at RTX initiation-were mostly ANCA positive (86% PR3-ANCA, 3% MPO-ANCA and 10% ANCA negative) at diagnosis and had renal (59%), pulmonary (66%) and orbital-subglottic (62%) involvements. At RTX initiation, patients had a median disease duration of 57 months (range 2270) and they had received a median total CYC cumulative dose of 17 g (range 0250).
RTX treatment was initiated as two 1-g infusions 2 weeks apart with co-administration of methylprednisolone 125 mg, paracetamol 1000 mg and either cetirizine 10 mg or polaramine 4 mg (RA protocol). Due to the observed RTX efficacy and the relapsing nature of GPA, RTX was then re-administered pre-emptively either as a 2 g infusion (1 g twice during a fortnight) annually or as a 1 g infusion biannually (1 g every 6 months). RTX 1 g biannually became the preferred maintenance regimen, as it was found to better sustain B cell depletion than the 2 g annually regimen. During maintenance, 12 (41%) patients received the 1 g biannually regimen, 6 (21%) patients received the 2 g annually regimen and 11 (38%) patients alternated between regimens.
RTX was added to other immunosuppressive drugs (IDs) (other than prednisolone) in 27 patients (93%), while 2 patients (7%) received RTX in monotherapy. Nine patients (31%) were given RTX in combination with a median CYC dose of 5 g (range 2.86). The median duration of combination treatment of RTX with other IDs was 24 months (range 154). The timing and pace of ID discontinuation was at the discretion of the treating physician, whereas the daily prednisolone dose was tapered from a median of 22.5 mg at baseline and discontinued in a protocolized manner. Patients received a median cumulative RTX dose of 9 g (range 513) and were followed a median of 49 months (range 1988) after RTX initiation. At the last visit, 17 patients (59%) were still treated with longterm pre-emptive RTX and almost all (except for 3 patients) had discontinued other IDs. Twelve patients (41%) had discontinued RTX mainly due to clinical concerns about hypogammaglobulinaemia (67%) and recurrent infections (42%). One patient (3%) died during the study period.
A fixed set of blood tests (including ANCA, Ig class quantification and flow cytometric immunophenotyping of lymphocytes) was performed prior to RTX initiation and before each new re-treatment until either 30 September 2011 (the closing date of this study), regardless of ongoing therapy, or shortly before the start of IVIG administration due to hypogammaglobulinaemia and/or infections. Ig levels were measured by nephelometry, with normal ranges defined as IgG 7.016.0 g/l, IgA 0.74.0 g/l and IgM 0.42.3 g/l. Total Ig was defined as the sum of IgG, IgA and IgM serum levels. The lowest levels of Ig during long-term RTX maintenance-nadir Ig levels-were recorded. The decrease in Ig between each RTX 2 g increment at 2, 4, 6 and 8 g of RTX was determined. Hypogammaglobulinaemia was defined as total Ig <6 g/l.
Data were analysed with SPSS version 20.0 (SPSS, Chicago IL, USA). Descriptive studies were first performed to assess Ig levels and lymphocyte subtypes for each 2 g RTX increment. Linear regression models were afterwards used to identify factors predicting levels for each Ig class during RTX long-term pre-emptive maintenance; the linear regression fit was assessed by visual inspection of the residuals plot. Patients that discontinued due to hypogammaglobulinaemia were compared with the remaining patients from the cohort (control group). The difference in immunoglobulin serum levels and their decline between groups were analysed using MannWhitney U tests. KaplanMeier survival curves were used to identify factors responsible for RTX discontinuation due to hypogammaglobulinaemia. Finally, logistic binary regression and Cox proportional hazard models-unadjusted and multivariate analysis with backward Wald selection (variable removed if P > 0.1)-were used to determine individual risk factors and the most important single risk factor for hypogammaglobulinaemia. P-values <0.05 were considered significant.
Results

Changes in Ig levels
About 30% of the patients had low levels of IgG (<7 g/l) and/or IgM (<0.4 g/l) prior to RTX initiation. The proportion of patients with low levels IgG and/or IgM increased to about 60% after the administration of 2 g RTX and to www.rheumatology.oxfordjournals.org about 70% after 6 g RTX. The proportion of patients with low IgA (<0.7 g/l) increased from 7% after 2 g RTX to 29% after 10 g RTX. None of the patients was hypogammaglobulinaemic prior to RTX initiation, but 11% and 16% were hypogammaglobulinaemic after RTX 2 g and RTX 6 g, respectively (Table 1) .
Median levels of total Ig and its classes showed a continuous decrease under long-term RTX maintenance (Table 1) . However, the largest decrease was seen after the first 2 g of RTX, with the decrease becoming less pronounced in the following rounds ( Fig. 1 ). In contrast, NK and CD4 cell counts as well as the CD4/CD8 ratio increased ( Table 1) .
Predictors of Ig levels during RTX maintenance
Ig levels during long-term pre-emptive RTX maintenance were partly dependent on the levels of Ig at baseline-except for IgA (R 2 = 0.079, P = 0.076) (see supplementary   Table S1 , available at Rheumatology Online). This relationship was particularly strong with IgM (R 2 = 0.561, P < 0.001), and to a lesser extent with IgG (R 2 = 0.179,
Male gender and older age decreased Ig levels, except for IgA. Men had a 2 g/l lower IgG level at the nadir compared with women during long-term RTX maintenance. The RTX cumulative dose did not predict the levels of any Ig classes during long-term RTX maintenance. On the other hand, the cumulative CYC dose significantly decreased IgG (R 2 = 0.107, P = 0.047) and IgA (R 2 = 0.133, P = 0.029) levels. The CD4 cell count at baseline did not predict levels of any Ig classes, although a higher CD4 cell count at baseline seemed to protect against lower IgG levels (R 2 = 0.065, P = 0.098). The variability of Ig levels during long-term RTX maintenance-determined by multiple linear regression models with backward selection-differed in Ig classes. Age, total CYC cumulative dose and baseline IgG level explained 40% of the variability in the IgG level during RTX maintenance, while male gender, total CYC cumulative dose and baseline IgM level explained 67% of the variability in IgM. However, the total CYC cumulative dose was the lone predictor of IgA level, explaining only 13% of its variability.
RTX discontinuation due to hypogammaglobulinaemia
Patient characteristics
Eight patients (28%) discontinued RTX due to hypogammaglobulinaemia. They had their first episode of Ig results missing in one patient after RTX 2 g and after RTX 4 g.
FIG.
1 Mean of total Ig decline after every RTX 2 g increment P-value determined by paired sample t-tests. RTX: rituximab.
hypogammaglobulinaemia a median of 63 weeks (range 17212) from RTX initiation before they discontinued RTX after a median of 189 weeks (range 100356). Hypogammaglobulinaemia was complicated in six patients: two patients had concomitant severe infections, three had recurrent infections and two had late-onset neutropenia. These patients were mostly male, had received a higher CYC cumulative dose and received the 1 g RTX biannually maintenance regimen (Table 2) . Five patients had kidney involvement without orbital-subglottic involvement, whereas one patient had orbital-subglottic involvement without kidney involvement. Three of these eight patients had had a previous episode of transient hypogammaglobulinaemia (total Ig levels ranging from 3.7 to 5.0 g/l) before RTX initiation (a median of 3 years from GPA diagnosis) while receiving CYC.
In addition to the eight patients who discontinued RTX, five other patients had hypogammaglobulinaemia during RTX maintenance, without RTX being discontinued. One patient had two episodes of hypogammaglobulinaemia, but none had transient hypogammaglobulinaemia before RTX initiation. They had their first episode of hypogammaglobulinaemia 108 weeks (range 80218) from RTX initiation lasting 32 weeks (range 16156) and they continued RTX maintenance for 291 weeks (range 156365) before censoring. One patient eventually discontinued during the study period after receiving a renal transplant.
Five patients received IVIG due to hypogammaglobulinaemia and four of them discontinued RTX.
RTX survival time
The mean drug survival time on RTX in our cohort was 304 weeks (95% CI 268, 340). RTX survival time in men was almost 2 years shorter than in women (261 vs 347 weeks, P = 0.017). Patients with kidney involvement had a shorter mean RTX survival time (275 vs 346 weeks, log rank P = 0.047). On the other hand, patients with orbital-subglottic involvement had a longer mean RTX survival time (334 vs 228 weeks, log rank P = 0.056). There was no difference in mean RTX survival time for patients with lung involvement (298 vs 312 weeks, log rank P = 0.696) (see supplementary Fig. S1 , available at Rheumatology Online).
RTX maintenance regimens played an important role in RTX survival time: the 1 g biannually regimen decreased significantly the mean RTX survival time compared with the 2 g annually regimen and the combination of both regimens (log rank P = 0.027) (Fig. 2) .
Risk factors for discontinuing RTX due to hypogammaglobulinaemia
Total Ig levels in patients who discontinued RTX due to hypogammaglobulinaemia had an early decline after the first 2 g RTX but also a late decline after a cumulative dose of RTX >6 g compared with the control group ( Fig. 3 and supplementary Table S2 , available at Rheumatology Online). IgA levels after 2 g RTX seemed to be the single most important risk factor for discontinuing RTX due to hypogammaglobulinaemia during long-term RTX maintenance [odds ratio (OR) = 0.01, P = 0.069], adjusted for gender after backward Wald selection (see supplementary  Table S3 , available at Rheumatology Online).
It is of interest that patients who discontinued RTX due to hypogammaglobulinaemia had a lower CD4 cell count after the administration of RTX 2 g (0.26 vs 0.39 Â 10 9 /l, P = 0.075) and RTX 4 g (0.24 vs 0.50 Â 10 9 /l, P = 0.010) compared with the control group (see supplementary  Table S2 , available at Rheumatology Online).
In unadjusted Cox proportional hazard regression models, male patients and those treated with the 1 g biannually regimen were eight times more likely to discontinue RTX during long-term maintenance due to hypogammaglobulinaemia (Table 3) . A 10 g increment in www.rheumatology.oxfordjournals.org the CYC cumulative dose increased the risk for discontinuing RTX due to hypogammaglobulinaemia by 14%, while orbital-subglottic involvement decreased the risk by 77% (P = 0.080) ( Table 3) . Male gender and the 1 g biannually regimen for RTX maintenance were the most independent predictors for discontinuing RTX due to hypogammaglobulinaemia [hazard ratio (HR) = 8.7, P = 0.050 and HR = 8.4, P = 0.037, respectively) after backward Wald selection (Table 3) .
Discussion
In GPA patients treated with long-term pre-emptive RTX maintenance, our study showed that the largest serum Ig decrease occurred after the first 2 g of RTX and that the RTX cumulative dose did not influence Ig levels, whereas the cumulative CYC dose did. Male gender and the 1 g biannually regimen were risk factors for RTX discontinuation due to hypogammaglobulinaemia. Previous studies in AAV/GPA reported a decline in Ig levels during long-term remission maintenance with RTX, but the studies had different maintenance strategies [810] . The proportion of patients with low IgG or IgM at baseline in our study was similar to the study by Smith et al. [9] , but started to diverge after the administration of RTX 6 g, as 70% of our patients had low IgG or IgM by then. Our study included patients treated with RTX in combination with other IDs, whereas the study of Smith et al. [9] included mostly patients treated with RTX monotherapy (97%). Neither this study nor the study of Venhoff et al. [17] showed lower Ig levels with the concomitant use of IDs during RTX maintenance, despite the fact that in our study, patients treated longer with concomitant IDs had received a higher CYC cumulative dose (data not shown).
Our study shows clearly that GPA patients are different from RA patients in terms of Ig serum levels at RTX initiation and during maintenance. At baseline, 3.5% of the RA patients treated with RTX from the Autoimmunity and Rituximab (AIR) registry had low IgG levels [14] , compared with 30% in our study. RA patients had a gradually increased incidence of low IgM levels (10% after the first round and 40% after the fifth RTX round) [13, 18] during long-term RTX re-treatment, while the prevalence of low IgG levels was either stable (36%) [13] or increased to a lesser extent (12% after the first round to 22% after the fifth round) [18] . CYC use prior to RTX administration in GPA patients might explain lower IgG and IgA levels during RTX maintenance. A 10 g CYC cumulative dose increment increased the risk of discontinuing RTX due to hypogammaglobulinaemia, confirming the synergistic effect of CYC and RTX in GPA patients [17] . Moreover, CYC-induced hypogammaglobulinaemia before RTX initiation could also increase the risk of discontinuing RTX due to hypogammaglobulinaemia during long-term maintenance.
In our study, patients that discontinued RTX due to hypogammaglobulinaemia had an early and a late decline of their total Ig levels during RTX long-term pre-emptive maintenance. The type of RTX maintenance regimen could explain this double-dip in Ig levels. The 1 g biannually RTX maintenance regimen increased the risk of hypogammaglobulinaemia compared with the 2 g annually regimen (used in RA). Therefore, allowing B cell recovery during RTX maintenance could prevent hypogammaglobulinaemia. Other maintenance strategies allowing B cell repopulation after each re-treatment [10] or after 2 years 2 KaplanMeier analysis of the probability of discontinuing rituximab due to hypogammaglobulinaemia according to the type of maintenance regimen and an RTX cumulative dose of 6 g [9] have not reported an increased risk in hypogammaglobulinaemia while patients had an equivalent follow-up time and received the same RTX cumulative dose.
Low levels of Ig at initiation, and especially after the first 2 g of RTX, increased the risk of hypogammaglobulinaemia. IgA levels usually remained stable under RTX maintenance [13, 19] , and interestingly, RA patients with raised IgA levels had a less robust clinical response and earlier B cell repopulation coincident with relapse [19] . In our study, IgA levels after the first 2 g of RTX seemed to be a reliable independent marker in identifying patients at risk for hypogammaglobulinaemia during RTX long-term pre-emptive maintenance, as nadir IgA levels were less dependent on their baseline levels and independent of gender and age. Low IgA levels (<1.0 g/l) could reflect a deeper B cell depletion.
In our study, CD4 and NK cell levels increased while Ig decreased during long-term B cell depletion. Of interest, B cell depletion by RTX at induction in non-sensitized patients undergoing renal transplantation increased the risk of acute cellular rejection in the first 3 months after transplantation [20] . These consequences of B cell depletion by RTX could also be explained by non-depleted B cells as they enhanced CD4 cells proliferation in vitro [21] .
GPA patients with orbital-subglottic involvement seemed to have a reduced risk of discontinuing RTX due to hypogammaglobulinaemia, whereas GPA patients with kidney involvement seemed to have a higher risk. Toxic effects from aggressive immunosuppressive therapies and renal capillary leakage could increase the risk of hypogammaglobulinaemia in GPA patients with kidney involvement [22] . But it is also possible that GPA patients with kidney involvement are generally more immunodeficient compared with patients with orbital-subglottic involvement.
Our retrospective study had some limitations, mainly due to the small sample size, making subgroup analysis prone to type II errors of not detecting differences and to wide CIs in both the logistic binary regression and Cox proportional hazard models analysis. But the longitudinal data were collected prospectively in a disease registry from a single tertiary centre. We also analysed patients who discontinued RTX due to hypogammaglobulinaemia, reflecting a more severe phenotype complicated by infections. RTX discontinuation based purely on isolated hypogammaglobulinaemia could have major consequences for ensuing remission maintenance therapy in GPA patients. Further studies are needed to determine whether our findings are also valid in microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).
In conclusion, long-term pre-emptive treatment with RTX 1 g every 6 months increased the risk of discontinuation due to hypogammaglobulinaemia in GPA patients. Male gender, kidney involvement, exposure to CYC and low Ig serum levels at RTX initiation were independent risk factors, whereas the RTX cumulative dose did not influence this risk. As hypogammaglobulinaemia may limit the number of times anti-CD20-mediated B cell depletion can be carried out [3] , close monitoring of Ig and lymphocyte subtypes during maintenance is warranted, as hypogammaglobulinaemia with a low CD4/CD8 ratio is a known risk factor for severe infections in AAV [23] .
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Rheumatology key messages
. Compared with RA, rituximab maintenance in granulomatosis with polyangiitis had an increased risk for hypogammaglobulinaemia. . Granulomatosis with polyangiitis men with kidney involvement and prior cyclophosphamide exposure discontinued rituximab maintenance due to hypogammaglobulinaemia. . The 1 g biannually maintenance regimen in granulomatosis with polyangiitis increased the risk of hypogammaglobulinaemia, necessitating rituximab withdrawal.
